Human PD-1/PDCD1 Protein

产品信息(Product Info)

Recombinant Human PD-1/PDCD1 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Leu25-Gln167.[Accession | Q15116-1]

分子量大小(Molecular Weight)

The protein has a predicted MW of 17 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.


Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human PD-1 on Tris-Bis PAGE under reduced. The purity is greater than 95%.


The purity of Human PD-1 is greater than 95% as determined by SEC-HPLC.


Immobilized Human PD-1, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-PD-1 Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA (QC Test).

SPR Data

Human PD-1, His Tag captured on CM5 Chip via anti-his antibody can bind Mouse PD-L1, hFc Tag with an affinity constant of 92.49 nM as determined in SPR assay (Biacore T200).


Programmed cell death protein 1, also known as PD-1 and CD279 , is a protein found on the surface of cells that has a role in regulating the immune system's response to the cells of the human body by down-regulating the immune system and promoting self tolerance by suppressing T cell inflammatory activity.


PDCD1; PD1; CD279; SLEB2; PD-1


(1)Blank C , Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion[J]. Cancer Immunology Immunotherapy, 2007, 56(5):739-745.